SCLERA LLC is a specialized contract research organization that evaluates potential "back of the eye" therapeutics for ameliorating blinding retinal disease such as diabetic retinopathy and neovascular AMD.
SCLERA LLC uses its patented intraocular implant technology to release specialized human growth factors slowly in the rabbit eye for induction of EITHER experimental retinal neovascularization (NV) for diabetic retinopathy OR experimental CNV for neovascular aging-related macular degeneration (nAMD).
SCLERA LLC provides clients with experimental models of various retinal diseases in large animal eyes (rabbit, pig, NHP) to test their potential therapeutics against retinal diseases.
As shown in the above slides, the 1.5 mm SCLERA implant that contains two human growth factors is placed in the mid-vitreous of the rabbit eye to induce experimental retinal neovascularization, thereby simulating diabetic retinopathy (Wong CG et al Curr Eye Research 2001).
Our pre-clinical efficacy studies demonstrate deep experience with retinal diseases that include both experimental diabetic retinopathy and neovascular (wet) aging-related macular degeneration.
SCLERA LLC 6965 El Camino Real , Suite 105, Carlsbad CA 92009 USA +1 (760) 505-1019
Accelerating the Discovery of Novel Ophthalmic Drugs
To Improve, Invent, and Innovate